Pyruvate improves myocardial tolerance to reperfusion injury by acting as an antioxidant: A chemiluminescence study

Background. There is indirect evidence that pyruvate improves myocardial tolerance to ischemia by scavenging oxygen radicals during reperfusion. The objectives of this study were to evaluate (I) lucigenin-enhanced chemiluminescence (LEC) as a method to measure. oxygen radical (OR) production in vitro and in vivo and (2) the antioxidant effect pyruvate during myocardial reperfusion. Methods. LEC was measured in vitro by adding to lucigenin (I) increasing concentrations of H2O2, (2) H2O2 and different concentrations of catalase, and (3) H2O2 plus pyruvate. isolated rat hearts per- fused with Krebs Henseleit-Lucigenin inside a chemilumescence chamber were subjected to equilibration, ischemia, and reperfusion, without (control) or with pyruvate. Developed pressure, contractability compliance, and chemiluminescence were recorded. Results. In vitro, LEC directly correlated with H2O2 concentrations (r(2)= 0. 997) and decreased in the presence of catalase or pyruvate. During myocardial reperfusion there was a surge of chemiluminescence that peaked at 4 minutes. Pyruvate decreased the initial reperfusion peak (9.8 +/- 0.3 x 10(3) cpm in pyruvate group vs 12.4 +/- 0.9 x Id cpn in control; p < 0.05) and the total amount of chemiluminescence generated during reperfusion (65. 7 +/- 12 x Id in pyruvate group vs 117.1 +/- 8.2 x Id co counts in control; p < 0. Or). Pyruvate improved recovery of function after ischemia reperfusion. Conclusions. LEC is a sensitive indicator of H2O2, concentrations and can evaluate the effect of antioxidants in vitro. It is a continuous, sensitive, and direct measurement of OR production in vivo. LEC is ideal for the evaluation of antioxidant interventions and provides direct evidence that;pyruvate acts as an antioxidant while improving myocardial function during reperfusion.